Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical Limited has applied to the ASX for quotation of 43,392 new ordinary fully paid shares, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly expands the company’s share capital base, reflecting ongoing issuance under existing equity arrangements but without indicating any major change in its operational strategy or capital structure.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an Australia-listed biotechnology company (ASX: ACW) focused on developing medical therapies, with its ordinary fully paid shares traded on the Australian Securities Exchange.
Average Trading Volume: 5,347,573
Technical Sentiment Signal: Buy
Current Market Cap: A$181.9M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges

